Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Sezary Syndrome 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Brain Neoplasms 1

Interventions

fludarabine phosphate 19Whole-Body Irradiation 15Peripheral Blood Stem Cell Transplantation 15Mycophenolic Acid 15Tacrolimus 12Cyclosporine 11Cyclophosphamide 11Antilymphocyte Serum 11Busulfan 10Rituximab 7Methotrexate 7Etoposide 6Melphalan 5Flow Cytometry 5Radiotherapy 4Panobinostat 4Lenalidomide 4Filgrastim 4Everolimus 4Dexamethasone 4Calcium Dobesilate 4thymoglobulin 3romidepsin 3pembrolizumab 3mogamulizumab 3fludarabine 3Therapeutics 3Sirolimus 3In Situ Hybridization, Fluorescence 3Immunohistochemistry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sezary Syndrome × O(6)-benzylguanine × Clear all
NCT00961220 2018-05-22

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 6 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡